Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 35, 2017 (suppl; abstr 4505).
Nieuwe tool biedt inzicht in gevolgen borstkanker tot 14 jaar na diagnose
feb 2022 | Borstkanker